Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a "3+0" schedule.
Sylvia Becker-DrepsBryan BletteRafaela BriceñoJorge AlemánMichael G HudgensGilberto MorenoAna OrdoñezJulio RochaDavid J WeberErick AmayaPublished in: PloS one (2017)
During the first five years of program implementation, reductions were observed in health facility visits for pneumonia in immunized age groups and infant mortality, which would be hard to achieve with any other single public health intervention. Future study is warranted to understand whether the lack of a booster dose (e.g., at 12 months) may be responsible for the small reductions in pneumonia hospitalizations observed in one year-olds as compared to infants.
Keyphrases
- public health
- risk factors
- healthcare
- cardiovascular events
- quality improvement
- randomized controlled trial
- primary care
- respiratory failure
- mental health
- cardiovascular disease
- coronary artery disease
- cancer therapy
- health information
- type diabetes
- intensive care unit
- extracorporeal membrane oxygenation
- health promotion